Clinical Trials Logo

Filter by:
NCT ID: NCT06381830 Recruiting - Lymphoma, B-Cell Clinical Trials

Clinical Study of CAR-T Cell Therapy Following ASCT for R/R B-cell Non-Hodgkin's Lymphoma

Start date: January 1, 2024
Phase: Phase 2
Study type: Interventional

The study is designed to evaluate the efficacy and safety of chimeric antigen receptor T-cell therapy following autologous stem cell transplantation for relapsed/refractory B-cell Non-Hodgkin's lymphoma.

NCT ID: NCT06381817 Recruiting - Clinical trials for Haploidentical Hematopoietic Stem Cell Transplantation

Haplo-cord HCT vs. Haplo-HCT for T-ALL Patients

Start date: April 1, 2024
Phase: Phase 3
Study type: Interventional

The goal of this clinical trial is to learn if haploidentical hematopoietic cell transplantation combined with an unrelated cord blood unit (haplo-cord HCT) works to treat acute T cell lymphoblastic leukemia (T-ALL). It will also learn about the safety of the transplantation. The main questions it aims to answer are: Dose co-infusion of cord blood in haploidentical hematopoietic cell transplantation (haplo-HCT) lower the rate of relapse? What medical problems do participants have when having haplo-cord HCT? Researchers will compare haplo-cord HCT to haplo-HCT to see if haplo-cord HCT works to treat T-ALL. Participants will be infused an unrelated cord blood unit at the same day of haploidentical graft infusion.

NCT ID: NCT06381323 Recruiting - Clinical trials for Primary Aldosteronism

The Clinical Efficacy and Safety of Finerenone in the Treatment of Primary Aldosteronism

Start date: March 1, 2024
Phase: Phase 4
Study type: Interventional

The purpose of our research is to clarify the therapeutic efficacy and safety of Finerenone in patients with Primary Aldosteronism and explore the effective clinical predictive indicators of Finerenone in the treatment of Primary Aldosteronism.

NCT ID: NCT06381271 Recruiting - Clinical trials for Aortic Valve Regurgitation

Transcatheter Aortic Valve Replacement for Pure Severe Aortic Valve Regurgitation

Start date: October 30, 2018
Phase:
Study type: Observational

The purpose of this multicenter, prospective and observational registry is to evaluate the safety and efficacy of TAVR for treatment of pure severe aortic valve regurgitation. Baseline characteristics, procedural and clinical data will be collected

NCT ID: NCT06381050 Not yet recruiting - Clinical trials for Advanced Solid Tumors

The Clinical Study of SHR-7631 for Injection in Patients With Advanced Solid Tumors

Start date: May 2024
Phase: Phase 1
Study type: Interventional

This study is an open-label, phase I clinical trial of SHR-7631 in patients with advanced solid tumors. The whole study is divided into three stages: dose escalation, dose expansion and efficacy expansion.

NCT ID: NCT06380972 Not yet recruiting - Forehead Contouring Clinical Trials

A Prospective, Randomized, No-treatment Controlled, Evaluator-blinded Clinical Trial to Evaluate the Efficacy and Safety of Polycaprolactone Microspherical Injectable to Improve Forehead Contour

Start date: May 2024
Phase: N/A
Study type: Interventional

A Prospective, Multicenter, Randomized, No-treatment-controlled, Evaluator-blinded, Superiority Clinical Trial to Evaluate the Efficacy and Safety of Polycaprolactone Based Facial Injectable to Improve Forehead Contour

NCT ID: NCT06380881 Recruiting - Clinical trials for Patients With Bone Metastases

PK/PD Study of SHR-2017 Injection in Patients With Bone Metastases

Start date: May 20, 2024
Phase: Phase 1
Study type: Interventional

To evaluate the pharmacokinetic characteristics, pharmacodynamic characteristics, safety, tolerability and immunogenicity of SHR-2017 injection in patients with bone metastases, and to evaluate the efficacy of SHR-2017 injection in the treatment of skeletal-related event and cancer pain.

NCT ID: NCT06380868 Enrolling by invitation - Diabetes Clinical Trials

IVI-guided Versus Angiography-guided PCI in Patients With Diabetes Mellitus

IVI-DIABETES
Start date: June 10, 2024
Phase: N/A
Study type: Interventional

Intravascular ultrasound (IVUS) serves as a beneficial instrument during percutaneous coronary intervention (PCI) procedures, affording insight into lesion characteristics and stent implantation. The ULTIMATE trial recently evidenced that IVUS-guided Drug-Eluting Stent (DES) implantation notably ameliorated clinical outcomes in all-comers, especially in patients who underwent an optimal procedure defined by IVUS, as opposed to angiography guidance, resonating with findings from the IVUS-XPL study, OCTOBER trial, and RENOVATE COMPLEX PCI trial, further confirmed by more recent IVUS-ACS trial. Optical coherence tomography (OCT) has a resolution 10 times higher than that of IVUS and can provide valuable information at each step of PCI. Regrettably, a dearth of prospective, randomized, multicenter trials exists that scrutinize the benefits of IVI-guided as opposed to angiography-guided PCI in patients suffering from diabetes mellitus. However, several trials have presented subgroup analyses reporting the reduction of clinical events by IVUS but not OCT guidance in patients with diabetes mellitus, which served as the foundation for the design of this trial.

NCT ID: NCT06380855 Recruiting - Rectal Cancer Clinical Trials

Flexible Colonoscope Assisted Hybrid Transanal Total Mesorectal Resection (taTME)

Start date: August 24, 2022
Phase:
Study type: Observational

The investigators propose to use flexible endoscopy combined with transanal total mesorectal resection to further reduce anal injury.

NCT ID: NCT06380777 Recruiting - Sarcopenia Clinical Trials

Establishment and Application of Digital Diagnosis and Treatment System for Sarcopenia

Start date: September 1, 2023
Phase:
Study type: Observational [Patient Registry]

The goal of this observational study is to establish a digital diagnosis and treatment system for sarcopenia, integrating research outcomes into a unified approach encompassing a digital vaccine (early warning screening model), digital drug (intervention model associated with pathogenesis), and digital rehabilitation (preventive system combining early warning and treatment). This aims to create a digital visual tertiary prevention network for sarcopenia. Research aims: Evaluate the effectiveness of the digital vaccine through a cross-sectional epidemiological survey. Establish a specialized cohort for sarcopenia through a longitudinal investigation, implementing the digital drug and digital rehabilitation interventions. Participants will: Engage in screening and assessment based on inclusion and exclusion criteria. Be monitored longitudinally, with tailored interventions for those with muscle atrophy and regular follow-ups for at-risk individuals. Key outcomes will focus on sarcopenia indicators, serum biomarkers, and clinical endpoints such as fracture rates, weakness classification, and quality of life.